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MYC and EIF3H Coamplification Significantly Improve
Response and Survival of Non-small Cell Lung Cancer
Patients (NSCLC) Treated with Gefitinib
Federico Cappuzzo, MD,* Marileila Varella-Garcia, PhD,† Elisa Rossi, PhD,‡ Sujatha Gajapathy, PhD,†
Marialuisa Valente, PhD,* Harry Drabkin, MD,§ and Robert Gemmill, PhD§
Background: We investigated the incidence of eukaryotic transla-
tion initiation factor 3 subunit H (EIF3H) and MYC amplification in
non-small cell lung cancer (NSCLC) patients, and whether MYC/
EIF3H increased gene copy number affected response to Epidermal
Growth Factor Receptor tyrosine kinase inhibitors.
Methods: Metastatic NSCLC patients (n  54) treated with ge-
fitinib were analyzed for the genomic content of EIF3H and MYC
genes by fluorescence in situ hybridization (FISH) using a custom-
designed 3-color DNA probe set.
Result: Amplification of EIF3H (ratio EIF3H/CEP8 2), was
observed in 10 cases (18.5%), andMYC was coamplified in all.MYC
amplification without coamplification of EIF3H was observed in 2
cases (3.7%). Receiver operating characteristic analysis was con-
ducted to identify the cutoff for MYC and EIF3H copy number best
discriminating sensitive and resistant populations. MYC FISH pos-
itive patients (MYC, mean 2.8) had a significantly higher re-
sponse rate (p  0.003), longer time to progression (p  0.01) and
overall survival (OS: p 0.02) thanMYC (mean2.8). Similarly,
EIF3H FISH positive patients (EIF3H, mean 2.75) had a sig-
nificantly higher response rate (p  0.002), longer time to progres-
sion (p  0.01) and OS (p  0.01) than EIF3H (mean 2.75).
Conclusion: Our results indicate that MYC and EIF3H are fre-
quently coamplified in NSCLC and that a high copy number corre-
lates with increased epidermal growth factor receptor tyrosine ki-
nase inhibitors sensitivity.
Key Words: MYC, EIF3H, Gefitinib, EGFR, Tyrosine kinase in-
hibitor, Non-small cell lung cancer, FISH.
(J Thorac Oncol. 2009;4: 472–478)
Despite tangible progress made during the last few years,the prognosis of patients with non-small cell lung cancer
(NSCLC) is still disappointing. Recent therapeutic advances
include drugs targeting the Epidermal Growth Factor Recep-
tor (EGFR), such as the monoclonal antibody cetuximab,1 or
the orally available tyrosine kinase inhibitors (TKIs) gefitinib
and erlotinib.2
It is thought that EGFR-TKIs are more effective in
patients with certain clinical or biologic characteristics. How-
ever, the best method for patient selection is still controver-
sial. Available data suggest that the presence of activating
EGFR mutations identifies individuals with the highest
chance to have tumor shrinkage,3 while EGFR gene copy
number identifies patients with the highest benefit in terms of
survival.4–7 Conversely, the presence of a KRAS mutation
identifies individuals with the lowest chance of responding to
EGFR-TKI,8 with a possible detrimental effect on survival.9
Nevertheless, none of the above mentioned biomarkers ac-
counts for all sensitive or resistant cases, suggesting that
other factors associated with drug sensitivity could be useful
for improved patient selection.
Molecular cytogenetic analyses have indicated that gain
of the long arm of chromosome 8 (8q) is a frequent event in
many human malignant diseases, including lung cancer.10
MYC, localized at 8q24.1, is a well characterized oncogene
involved in cell growth, differentiation, and apoptosis.11 Pre-
vious studies reported that MYC amplification was associated
with tumor progression and a worse prognosis.12,13 In the
study conducted by Lockwood et al.,14 MYC was the most
frequent amplification observed in lung cell lines. A recent
analysis, conducted in 300 patients with gastric adenocarci-
noma, showed coamplification of MYC and either EGFR or
HER2,15 suggesting that MYC might influence the activity of
drugs targeting these receptors. Moreover, preliminary results
from the National Surgical Adjuvant Breast and Bowel B-31
trial suggested that HER2-positive breast cancer patients with
primary tumor MYC amplification derived more benefit from
trastuzumab, a monoclonal antibody against HER2, than
patients without MYC amplification.16,17
The eukaryotic translation initiation factor 3 (EIF3) is a
large multiprotein complex originally identified as a factor
that binds the 40S ribosomal subunit and prevents its associ-
ation with the 60S subunit. EIF3 consists of 13 putative
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subunits known as EIF3A-EIF3M.18 Various EIF3 subunits
have been found to have altered expression in malignant
tumors. In humans, overexpression of EIF3H has been found
in prostate, breast, and liver cancer.19–22 In many cases, this
seems to be due to amplification of the 8q23 region which
includes the EIF3H gene at 8q23.3. EIF3H amplification has
been observed in 20% of untreated primary breast cancer,
30% of hormone refractory prostate carcinoma19 and 26% of
hepatocellular carcinoma.20 High level amplification of the
EIF3H gene has also been associated with advanced stage
and poor prognosis prostate cancer.21 At the cellular level,
EIF3H overexpression increases proliferation, growth and
survival.23 Recent studies have demonstrated that EIF3H and
MYC are coamplified in prostate cancer, suggesting that there
may be cooperation between MYC and EIF3 to further up-
regulate translation initiation.24
Whether MYC and EIF3H are coamplified in lung
cancer, and whether this could affect anti-EGFR responses, is
unknown. Based on these premises, we evaluated MYC and
EIF3H gene status in patients with NSCLC treated with the
EGFR-TKI gefitinib.
PATIENTS AND METHODS
Patient Selection
The present retrospective study was conducted in a
cohort of NSCLC patients previously evaluated for EGFR
and HER2 gene copy number.4,25 Among the 102 patients
included in the original study, 54 had tumor tissue available
and were selected for the present analysis. No additional
clinical or biologic characteristic was used for patient selec-
tion. All patients had histologically confirmed NSCLC with
measurable, locally advanced or metastatic disease, progress-
ing or relapsing after chemotherapy, or with medical contra-
indications for chemotherapy. Patients were classified as
never smokers (100 cigarettes per lifetime), former smok-
ers (quit smoking more than 6 months before starting gefitinib
therapy), or current smokers (quit smoking less than 6 months
before starting gefitinib therapy or active smokers). Patients
received gefitinib (250 mg/d) and were evaluated for response
after 2 months according to the RECIST criteria.26 Tumor
response was assessed by computer tomography scan, with a
confirmatory evaluation repeated in patients with complete
response (CR), partial response, and stable disease at least 4
weeks after the initial determination of response. The study
population included 14 (26.4%) patients positive for EGFR
by fluorescence in situ hybridization (FISH). Eleven patients
(22.4%) had an EGFR mutation in exon 19 or 21 and 10
patients (21.7%) had a KRAS mutation. All patients received
at least one previous chemotherapy, including platinum in
80.4% of cases. The study was approved by the local Ethics
Committee and was conducted in accordance with ethical
principles stated in the most recent version of the Declaration
of Helsinki.
Tissue Preparation and FISH Analyses
Sections from paraffin-embedded tissue blocks contain-
ing representative malignant cells obtained at time of diag-
nosis were used for this analysis. Histopathological classifi-
cation was determined on hematoxylin-eosin stained sections
based on the World Health Organization criteria.27
DNA insert of the BAC clone NO 764P21, encompass-
ing sequences of the EIF3H gene, was amplified and labeled
by nick-translation using a Nick Translation Kit (Vysis/
Abbott Molecular Catalog#32-801300) and SpectrumGreen
conjugated dUTPs according to the manufacturer’s instruc-
tions. The labeled DNA was precipitated in the presence of
human Cot1 DNA. The chromosomal mapping and the hy-
bridization efficiency of the new reagent was tested in spec-
imens with normal karyotypes. Three-color FISH assays were
performed on blank 4 m, paraffin-embedded lung cancer
tissue sections, using the SpectrumGreen labeled EIF3H
probe, the LSI C-MYC SpectrumOrange and the CEP-8
SpectrumAqua commercial probes (Abbott Molecular) ac-
cording to standard protocol in the laboratory.
Initially the slides were incubated for 2 hours at 65°C,
deparaffinized in Citri-Solv (Fisher) and washed in 100%
ethanol for 5 minutes. The slides were sequentially incubated
in 2 SSC at 75°C for 10 to 18 minutes, digested in 0.25
mg/ml Proteinase K/2 SSC at 45°C for 10 to 18 minutes,
washed in 2 SSC for 5 minutes, and dehydrated in ethanol.
The probe mixture was prepared using 0.5 l of the stock
reagent of each of the commercial probes and 200 ng of DNA
from the EIF3H probe and applied to the selected hybridiza-
tion areas, which were covered with glass coverslips and
sealed with rubber cement. DNA denaturation was performed
for 15 minutes at 80°C and slides were incubated at 37°C for
24 to 48 hours. Posthybridization washes were performed
with 2 SSC/0.3% NP-40 at 72°C for 2 minutes. The slides
were then washed in 2 SSC for 1 minute, dehydrated in
ethanol and chromatin was counterstained with diamidino-2-
phenylindole (0.3 g/ml in Vectashield, Vector Laboratories,
Burlingame, CA). Analysis was performed on epifluores-
cence microscope using single interference filter sets for
green (fluorescein isothiocyanate), red (Texas red), aqua
(Aqua) and blue (diamidino-2-phenylindole) as well as dual
(red/green) and triple (blue, red, green) band pass filters. For
documentation, images were captured using a charge- cou-
pled device camera and merged using dedicated software.
Statistical Analysis
The primary end-point of the study was the association
of MYC and EIF3H gene copy number with response to
gefitinib therapy. Analysis of receiver operating characteristic
(ROC) curve was carried out with the aim of determining a
cutoff point for MYC and EIF3H gene copy numbers as a
continuous variable.28 Sensitivity and specificity were ex-
pressed in terms of percentage and the highest value has been
chosen as the best cutoff point. Secondary end-points were
association with time to progression (TTP) and overall sur-
vival (OS). TTP was calculated from the time of first gefitinib
dose administration to time of disease progression or last
disease assessment. OS was calculated from the time of first
gefitinib dose administration to patient death or last contact.
Differences in response rate (RR) were compared by
Fisher’s exact test or 2 test. TTP, OS, and the 95% confi-
dence intervals were evaluated by survival analysis using
Kaplan-Meier method.29 TTP and OS for the groups with
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negative and positive biomarker were compared using the
log-rank test. Statistical significance was set at 0.05 for
each analysis. All statistical analyses were performed using
SPSS version 11.5.1 (SPSS Italia srl, Bologna, Italy).
RESULTS
Patient Characteristics
Characteristics of the 54 patients included in the study
are shown in Table 1. The median age was 61 years (range
25–79), the majority of patients were male (64.8%), and most
were former or current smokers (85.2%) with a good perfor-
mance status (ECOG PS 0–1: 90.7%). Adenocarcinoma was
the most frequent histologic type (55.6%). In the study
population, the overall response rate was 17.0%, including 1
CR and 8 partial responses (PR). The disease control rate,
including CR, PR, and stable disease, was 41.5%, median
TTP was 3.5 months, and median survival was 11.0 months.
EGFR FISH and mutation status was known in 53 and 49
patients, respectively. EGFR was positive by FISH in 14
(26%) cases and by mutation in 11 (22%). Response rate was
significantly higher in EGFR FISH positive than in negative
(50% versus 5%, p  0.001) and in patients with EGFR
mutations than in EGFR wild type (63% versus 2%, p 
0.0001).
Outcome According to MYC Gene Copy Number
As shown in Table 2, FISH analysis for MYC was
successfully performed in all patients. Median mean MYC
gene copy number was 2.92 copies/cell (range 1.52–12.38).
Amplification of MYC (ratio MYC/CEP8 2), was observed
in 12 cases (22.2%). In the ROC analysis, a cut-off of MYC
copy number per cell at 2.8 identified an area under the curve
of 0.78 (Figure 1A). Using this cutoff, 25 specimens (46.3%)
were MYC FISH negative (mean per cell 2.78) and 29
(53.7%) were MYC FISH positive (mean per cell 2.8
copies). Among the 29 MYC FISH positive patients, 7 were
EGFR FISH positive and EGFR mutated, 4 were EGFR FISH
positive, 1 harbored an EGFR mutation and 5 harbored a
KRAS mutation. Increased MYC gene copy number was not
associated with any statistically significant clinical or bio-
logic characteristic, even though the MYC FISH positive
patients were more frequently EGFR FISH positive, EGFR
mutated and never smokers. The RR significantly favored
MYC FISH positive overMYC FISH negative patients (31.0%
versus 0%, p  0.003), as well as TTP (4.4 versus 2.6
months, p  0.014) and OS (13.8 versus 6.4 months, p 
0.025), as shown in Table 2 and Figure 2. In the small
subgroup of EGFR FISH positive or EGFR mutated patients
(n  17), all responders were MYC FISH positive (66.0% in
EGFR positive/MYC positive versus 0% in EGFR positive/
MYC negative, p  0.04).
Outcome According to EIF3H Gene Copy
Number
EIF3H was successfully evaluated by FISH in all cases
(Table 2). Median mean EIF3H gene copy number was 2.79
copies/cell (range 1.65–5.02). Amplification of EIF3H (ratio
EIF3H/CEP8 2), was observed in 10 cases (18.5%), and
MYC was coamplified in all (Figure 3). There were only two
cases with MYC amplification in which EIF3H was not
coamplified. Using a ROC analysis (Figure 1B), a cutoff of
EIF3H copy number per cell at 2.75 identified an area under
the curve of 0.84. Using this cutoff, 28 specimens (51.8%)
were EIF3H FISH positive (mean per cell 2.75 copies) and
26 (48.2%) were EIF3H FISH negative (mean per cell
2.75). As was the case for MYC, increased EIF3H gene
copy number was not associated any statistically significant
clinical or biologic characteristic. Nevertheless, EIF3H FISH
positive cases were more frequently never smokers and
EGFR positive either by FISH or mutated. Interestingly, all
EIF3H FISH positive patients were also MYC FISH positive,
and this association was statistically significant (p 0.0001).
EIF3H FISH positive patients had a significantly higher RR
(32.1% versus 0%, p  0.002), significantly longer TTP (4.4
versus 2.7 months, p  0.01) and OS (17.8 versus 6.4
months, p  0.01) than EIF3H FISH negative, as shown in
TABLE 1. Patient Characteristics
Characteristics Total %
Total 54
Median age (year, range) 61 (25–79)
Gender
Male 35 64.8
Female 19 35.2
Smoking history
Never 8 14.8
Former 22 40.8
Current 24 44.4
Histology
Adenocarcinoma  bronchioloalveolar 35 64.8
Squamous cell carcinoma 12 22.2
Other 7 13.0
ECOG performance status
0 33 61.1
1 16 29.6
2 5 9.3
Total evaluated for EGFR FISH 53
Positive 14 26.4
Negative 39 73.6
Total evaluated for EGFR mutation 49
Exon 19 7 14.3
Exon 21 4 8.1
Wild type 38 77.6
Total evaluated for KRAS mutation 46
Mutated 10 21.7
Wild type 36 78.3
Total evaluable for response to gefitinib therapy 53
Complete response 1 1.9
Partial response 8 15.1
Stable disease 13 24.5
Progressive disease 31 58.5
Time to progression (mo) 3.5
Median survival (mo) 11.0
EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization;
ECOG, Eastern Cooperative Oncology Group.
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Table 2 and Figure 4. In the small cohort of patients that were
EGFR FISH positive or harbored an EGFR mutation (n 
17), all responders were EIF3H FISH positive and vice versa
(p  0.01).
DISCUSSION
The present study, conducted in a NSCLC population
exposed to the EGFR-TKI gefitinib, for the first time dem-
onstrated that MYC and EIF3H are frequently coamplified in
NSCLC and this event could affect drug sensitivity. Patients
with MYC or EIF3H increased gene copy number had better
outcomes in terms of response, TTP and survival than indi-
viduals lacking MYC/EIF3H gene gain.
Previous studies have reported that amplification of 8q
may be involved in cancer progression.10 The two genes
evaluated in our study,MYC and EIF3H, have been suggested
to be putative target genes in 8q23–q24.22,30,31 These two
genes are frequently coamplified in recurrent hormone-refrac-
tory prostate cancer21 and in breast cancer, but they were not
always included in the same amplicon.19,32 Nevertheless,
Nupponen et al.,32 based on the amplicon mapping and gene
expression data, reported that the strongest candidate target
FIGURE 1. Receiver Operating Character-
istic (ROC) curves for MYC (A) and eukary-
otic translation initiation factor 3 subunit H
(EIF3H) (B). The value best discriminating
responders versus nonresponders to ge-
fitinib therapy was a mean gene copy
number per cell of 2.8 for MYC and 2.75
for EIF3H.
TABLE 2. MYC/EIF3H Gene Copy Number, Patient Characteristics and Response to Gefitinib Therapy
Total Number MYC  (n/%) MYC  (n/%) p EIF3H  (n/%) EIF3H  (n/%) p
Gender 54 29 25 0.18 28 26 0.13
Male 35 16/55.2 19/76.0 15/53.6 20/77.0
Female 19 13/44.8 6/24.0 13/46.4 6/23.0
Smoking 54 29 25 0.09 28 26 0.07
Never 8 7/24.1 1/4.0 7/25.0 1/3.8
Former/current 46 22/75.9 24/96.0 21/75.0 25/96.2
Histology 54 29 25 0.12 28 26 0.17
Adenocarcinomaa 35 22/75.9 13/52.0 21/75.0 14/53.8
Other 19 7/24.1 12/48.0 7/25.0 12/46.2
EGFR FISH 53 29 24 0.07 28 25 0.19
Positive 14 11/37.9 3/12.5 10/35.7 4/16.0
Negative 39 18/62.1 21/87.5 18/64.3 21/84.0
EGFR mutation 49 28 21 0.4 27 22 0.32
Mutated 11 8/28.5 3/14.3 8/29.6 3/13.6
Wild type 38 20/71.5 18/85.7 19/70.4 19/86.4
KRAS mutation 46 27 19 0.80 26 20 0.92
Mutated 10 5/18.5 5/26.3 5/19.2 5/25.0
Wild type 36 22/81.5 14/73.7 21/80.8 15/75.0
Response to gefitinib 53 29 24 0.003 28 25 0.002
Responderb 9 9/31.0 0 9/32.1 0
Non responderb 44 20/69.0 24/100.0 19/67.9 25/100.0
Response in EGFRc 17 12 5 0.04 11 6 0.01
Responderb 8 8/66.6 0 8 0
Non responderb 9 4/33.4 5/100.0 3 6
a Adenocarcinoma category also included bronchioloalveolar carcinoma.
b Responder category included patients with complete and partial response; non responder category included patients with stable and progressive disease.
c EGFR  included patients with a positive FISH test or with an EGFR mutation.
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gene for the 8q23–q24 amplification was EIF3H. In the
present study, for the first time we have shown that EIF3H
and MYC are frequently coamplified in NSCLC and probably
these two genes are not included in the same amplicon.
Interestingly, many of the genes regulated by MYC affect
ribosome biogenesis and protein translation.33–35 Thus, coam-
plification of EIF3H and MYC may cooperate in enhanced
protein translation, either in a general way or for a specific
subset of mRNAs.
To perform this study, we developed a three-color
DNA probe set to simultaneously examine the copy number
of EIF3H, MYC and centromere eight sequences in lung
tumors, and were able to observe amplification of both
EIF3H and MYC in the same tumor cells. This finding
C
U
M
U
LA
TI
VE
 D
IS
TR
IB
U
TI
O
N
 F
U
N
C
TI
O
N
Time to Progression (months)
403020100
1,
,8
,6
,4
2
0,
Survival (months)
403020100
1,
,8
,6
,4
,2
0,
TTP OS
C
U
M
U
LA
TI
VE
 S
U
R
VI
VA
L
Median 4.4 versus 2.6 months Median 13.8 versus 6.4 months
p=0.01 p=0.02
MYC+
MYC+
MYC-
MYC-
FIGURE 2. The picture shows
time to progression and survival of
patients treated with gefitinib ac-
cording to MYC fluorescence in situ
hybridization (FISH) status. A mean
gene copy number per cell 2.8
qualified the sample as MYC posi-
tive.
FIGURE 3. Non-small cell lung
cancer (NSCLC) sections hybridized
with the MYC (SpectrumOrange)/
eukaryotic translation initiation factor
3 subunit H (EIF3H) SpectrumGreen/
CEP8 SpectrumAqua probe set
showing low copy numbers (A),
high copy numbers for the 3 tar-
gets (B) and coamplification of
MYC and EIF3H (C). EIF3H coampli-
fication was observed in 10 of 12
MYC amplified specimens.
OSTTP
C
U
M
U
LA
TI
VE
D
IS
TR
IB
U
TI
O
N
FU
N
C
TI
O
N 1,
Time to Progression (months) Survival (months)
C
U
M
U
LA
TI
VE
 S
U
R
VI
VA
L 
Median 4.4 versus 2.7 months
p=0.01
Median 17.8 versus 6.4 months
p=0.01
403020100
,8
,6
,4
,2
0,
1,
,8
,6
EIF3H+,4
,2 EIF3H-
0
0,
10 20 30 40
EIF3H+
EIF3H-
FIGURE 4. The picture shows
time to progression and survival of
patients treated with gefitinib ac-
cording to translation initiation fac-
tor 3 subunit H (EIF3H) fluores-
cence in situ hybridization (FISH)
status. A mean gene copy number
per cell 2.75 qualified the sample
as EIF3H positive.
Cappuzzo et al. Journal of Thoracic Oncology • Volume 4, Number 4, April 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer476
generates the hypothesis that coamplification and overexpres-
sion of EIF3H with MYC cooperatively shifts the repertoire
of actively translated mRNAs to a set of genes that drive
proliferation and growth, or inhibit apoptosis.
The possibility that MYC influences the efficacy of
agents targeting the EGFR family has been postulated in a
study conducted in breast cancer patients.16,17 In the National
Surgical Adjuvant Breast and Bowel B-31 clinical trial,
which compared treatment with chemotherapy versus chemo-
therapy plus trastuzumab, a total of 1549 patients were
evaluated for MYC, and 30% of patients displayed gene
amplification. Among patients with amplification of both
HER2 and MYC, the addition of trastuzumab to chemother-
apy reduced the risk of cancer recurrence by 76% and
reduced the risk of death by 64%, while in individuals with
HER2 amplification alone the addition of trastuzumab to
chemotherapy did not reduce the risk of death.16 In our study,
we observed that both MYC and EIF3H were associated with
a better outcome after gefitinib therapy, and among EGFR
patients (FISH and/or mutated), only individuals with in-
creased MYC/EIF3H gene copy number had a significant
tumor shrinkage. The mechanism responsible for the highest
sensitivity to anti-EGFR agents in presence of MYC/EIF3H
gene gain is not clear. The small number of patients included
in the present study and the strong association between the
clinical and biologic parameters did not allow us to assess the
value of different predictors in a multivariable model. Nev-
ertheless, preclinical data have demonstrated that drugs in-
terfering with the EGFR family inhibit expression and activ-
ity of MYC, suggesting that MYC-dependent tumors may be
more sensitive to anti-EGFR strategies.36–38 MYC expression
is known to induce apoptosis, which can be inhibited by signal-
ing from either the RAS and AKT pathways,39 antiapoptotic
molecules, i.e., BCL-2,40 or through the up-regulation of factors
such as MAD-1, which directly antagonize MYC function.41
Coamplification of EIF3H may also reduce MYC-dependent
apoptosis in prostate epithelial cells.42 If MYC up-regulation
was an early event in some tumors, then growth factor
signaling of EIF3H over-expression might provide a neces-
sary antiapoptotic signal. Finally, it is not possible to exclude
that other genes included in the amplicon could in some way
modulate drug sensitivity.
MYC gene amplification has been evaluated in several
solid tumors, including lung cancer.13,14,43 Conversely, to our
knowledge, no previous study investigated the incidence of
EIF3H gene amplification in lung tumors. Previous studies
reported a 13 to 23% incidence ofMYC amplification in small
cell lung cancer and 5 to 12% in NSCLC.12 In the study
conducted by Kubokura et al.,12 the incidence of MYC am-
plification in NSCLC was up to 88%, higher than reported in
other experiences including the present study probably be-
cause of the different and less stringent criteria used for
defining gene amplification. Interestingly, Kubokura study
showed that MYC amplification correlated with lymph node
metastasis, suggesting a possible negative effect on survival.
Although the absence of a control arm precludes the possi-
bility to discriminate between the predictive versus prognos-
tic effect of study genes, our results, together with the
possible negative prognostic effect of both EIF3H and
MYC12,13,21,22 suggest that those genes could represent a
favorable predictive factor for survival in patients exposed to
EGFR-TKIs.
In conclusion, our results showed for the first time that
MYC and EIF3H are coamplified in NSCLC and this biologic
event could positively affect the response and survival of
patients treated with EGFR-TKIs. These data originated from
a retrospective analysis and a prospective validation is war-
ranted.
ACKNOWLEDGMENTS
Supported by Italian Association for Cancer Research
(to F.C.), NCI-P30 CA046934 (CCSG), and NCI-P50 CA58187
(SPORE in Lung Cancer, to R.G. and H.D.).
REFERENCES
1. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized,
multicenter, phase III study of cetuximab in combination with cisplatin/
vinorelbine (CV) versus CV alone in the first-line treatment of patients
with advanced non-small cell lung cancer (NSCLC). J Clin Oncol
2008;26:6s (abstract 3).
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med 2005;353:
123–132.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
4. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefitinib sensitivity in non-small cell lung cancer.
J Natl Cancer Inst 2004A;97:643–655.
5. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer -
molecular and clinical predictors of outcome. N Engl J Med 2005;353:
133–144.
6. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR
as biomarkers of response to erlotinib in National Cancer Institute of
Canada clinical trial group study BR21. J Clin Oncol 2008;26:4268–
4275.
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of
outcome with gefitinib in a phase III placebo-controlled study in ad-
vanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034–5042.
8. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary
resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med
2005;2:e17.
9. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal
growth factor receptor and in KRAS are predictive and prognostic
indicators in patients with non-small-cell lung cancer treated with
chemotherapy alone and in combination with erlotinib. J Clin Oncol
2005;23:5900–5909.
10. Forozan F, Karhu R, Kononen J, et al. Genome screening by compara-
tive genomic hybridization. Trends Genet 1997;13:405–409.
11. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with
oligonucleotide microarrays reveals that MYC regulates genes involved
in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A
2000;97:3260–2365.
12. Kubokura H, Tenjin T, Akiyama H, et al. Relations of the c-myc gene
and chromosome 8 in non-small cell lung cancer: analysis by fluores-
cence in situ hybridization. Ann Thorac Cardiovasc Surg 2001;7:197–
203.
13. Bergh JC. Gene amplification in human lung cancer. The myc family
genes and other proto-oncogenes and growth factor genes. Am Rev
Respir Dis 1990;142:S20–S26.
14. Lockwood WW, Chari R, Coe BP, et al. DNA amplification is a
ubiquitous mechanism of oncogene activation in lung and other cancers.
Oncogene 2008;27:4615–4624.
15. Mitsui F, Dobashi Y, Imoto I, et al. Non-incidental coamplification of
Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas.Mod
Pathol 2007;20:622–631.
Journal of Thoracic Oncology • Volume 4, Number 4, April 2009 MYC and EIF3H Coamplification and Gefitinib Sensitivity
Copyright © 2009 by the International Association for the Study of Lung Cancer 477
16. Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer
with co-amplification of HER2 and cMYC suggests pro-apoptotic func-
tion of dysregulated cMYC in vivo. Breast Cancer Res Treat 2005;94
(abstract 46).
17. Reinholz MM, Dueck AC, Lingle WL, et al. The concordance between
NCCTG’s and NSABP’s C-myc FISH assays. J Clin Oncol 2008;26:
757s (abstract 22110).
18. Dong Z, Zhang JT. Initiation factor eIF3 and regulation of mRNA
translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006;59:
169–180.
19. Savinainen KJ, Linja MJ, Sarama¨ki OR, et al. Expression and copy
number analysis of TRPS1, EIF3S3 and MYC genes in breast and
prostate cancer, Br J Cancer 2004;90:1041–1046.
20. Okamoto H, Yasui K, Zhao C, et al. PTK2 and EIF3S3 genes may be
amplification targets at 8q23-q24 and are associated with large hepato-
cellular carcinomas. Hepatology 2003;38:1242–1249.
21. Sarama¨ki O, Willi N, Bratt O, et al. Amplification of EIF3S3 gene is
associated with advanced stage in prostate cancer. Am J Pathol 2001;
159:2089–2094.
22. Nupponen NN, Porkka K, Kakkola L, et al. Amplification and overex-
pression of p40 subunit of eukaryotic translation initiation factor 3 in
breast and prostate cancer. Am J Pathol 1999;154:1777–1783.
23. Savinainen KJ, Helenius MA, Lehtonen HJ, et al. Overexpression of
EIF3S3 promotes cancer cell growth. Prostate 2006;66:1144–1150.
24. Zhang L, Smit-McBride Z, Pan X, Rheinhardt J, et al. An oncogenic role
for the phosphorylated h-subunit of human translation initiation factor
eIF3. J Biol Chem 2008;283:24047–24060.
25. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2
gene copy number enhances response to gefitinib therapy in EGFR
positive Non-Small Cell Lung Cancer patients. J Clin Oncol 2005B;23:
5007–5018.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organiza-
tion for Research and Treatment of Cancer, National Cancer Institute of
the United States, National Cancer Institute of Canada. J Natl Cancer
Inst 2000;92:205–216.
27. Travis WD, Colby TV, Corrin B. Histological typing of lung and pleural
tumors, 3rd Ed. Berlin: Springer, 1999.
28. Cai T, Moskowitz CS. Semi-parametric estimation of the binomial ROC
curve for a continuous diagnostic test. Biostatistics 2004;5:573–586.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete obser-
vations. J Am Stat Assoc 1985;53:457–481.
30. Jenkins RB, Qian J, Lieber MM, et al. Detection of c-myc oncogene
amplification and chromosomal anomalies in metastatic prostatic carci-
noma by fluorescence in situ hybridization. Cancer Res 1997;57:524–
531.
31. Chang GT, Steenbeek M, Schippers E, et al. Characterization of a
zinc-finger protein and its association with apoptosis in prostate cancer
cells. J Natl Cancer Inst 2000;92:1414–1421.
32. Nupponen NN, Isola J, Visakorpi T. Mapping the amplification of
EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer
2000;28:203–210.
33. Boon K, Caron HN, van Asperen R, et al. N-myc enhances the expres-
sion of a large set of genes functioning in ribosome biogenesis and
protein synthesis. EMBO J 2001;20:1383–1393.
34. Schlosser I, Ho¨lzel M, Mu¨rnseer M, et al. A role for c-Myc in the
regulation of ribosomal RNA processing. Nucleic Acids Res 2003;31:
6148–6156.
35. Dang CV, O’Donnell KA, Zeller KI, et al. The c-Myc target gene
network. Semin Cancer Biol 2006;16:253–264.
36. Neve RM, Sutterlu¨ty H, Pullen N, et al. Effects of oncogenic ErbB2 on
G1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647–
1656.
37. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast
tumor proliferation through modulation of p27(Kip1)-Cdk2 complex
formation: receptor overexpression does not determine growth depen-
dency. Mol Cell Biol 2000;20:3210–3223.
38. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-
targeted anticancer therapeutics is influenced by the availability of
epidermal growth factor-related peptides. Cancer Res 2002;62:3151–
3158.
39. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of
c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.
Nature 1997;385:544–548.
40. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between
c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554–556.
41. Jiang K, Hein N, Eckert K, et al. Regulation of the MAD1 promoter by
G-CSF. Nucl Acids Res 2008;36:1517–1531.
42. Zhang L, Smit-McBride Z, Pan X, et al. An oncogenic role for the
phosphorylated h-subunit of human translation initiation factor eIF3.
J Biol Chemistry 2008;283:24047–24060.
43. Shiraishi M, Noguchi M, Shimosato Y, et al. Amplification of protoon-
cogenes in surgical specimens of human lung carcinomas. Cancer Res
1989;49:6474–6479.
Cappuzzo et al. Journal of Thoracic Oncology • Volume 4, Number 4, April 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer478
